Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pepcid

Executive Summary

H2 antagonist sales grew 13% during the quarter. In recognition of the upcoming loss of exclusivity for Pepcid, Merck tried to minimize the significance of the increase. Underlying prescriptions were down 15%-20%, Jordan said, and only an unusual inventory adjustment in the second quarter of 1999 led to the reported sales increase. "It is very important to remember that Pepcid is one of Merck's most aggressively priced products in terms of rebates and discounts [and that] Pepcid carries a royalty to a third party," she added. Merck reports gross sales without adjustments for rebates and other payments
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS036428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel